

What: Vaccine Committee Agenda  
When: April 21, 2022; 12:00-1:00 p.m. PT  
Where: Zoom Meeting

To register for the meeting, please review the [Public Comment Protocol](#) then email [wvameetings@wavaccine.org](mailto:wvameetings@wavaccine.org) at least two business days in advance of the meeting.

WVA Agendas are subject to revision up to and including the time of the meeting.

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

### Agenda for Vaccine Committee Meeting

Approx. Time	Pg.		Topic/[Anticipated Action]	Presented by:
12:00-12:05	Pg. 3-5	*	1. Introductions & Calendar Consent Items a. Vaccine Committee Minutes (November 4, 2021)	J. Zell / E. Marcuse
12:05-12:10	Pg. 6-12	*	2. 2022-23 Vaccine Assessment Grid	J. Zell / P. Miller
12:10-12:15			3. DOH Leadership	J. Jorgenson
12:25-12:25			4. Pediatric COVID-19 Vaccines a. DOH Update b. Future	DOH Update J. Dunn
12:25-12:55	Pg. 13-14	*	5. Status of Childhood Vaccine Coverage a. DOH Update b. WCAAP Initiatives c. PCIC Work d. Committee Perspectives	DOH Staff K. Rice C. Jenner Any
1:00			8. Closing	E. Marcuse

\*Indicates agenda item attached  
Red text indicates an action item

**April 21, 2022**

**WVA Meeting of the Vaccine Committee**

**Proposed Form of Votes**

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors and committee members.

**Items under Agenda Section 1:**

VOTED: To approve November 4, 2021 meeting minutes.

[To approve November 4, 2021 meeting with the changes suggested at the meeting.]

**Meeting Notes**  
**Vaccine Committee Meeting**  
**November 4, 2021; 12:00-1:00 p.m. PT**

**I. Attendance.** This meeting was conducted solely by webinar. Participating in all or part of the meeting were the following individuals:

<p>8 <u>Members &amp; Guests</u></p> <p>9 John Dunn, MD, FAAP, Acting Chair</p> <p>10 James Chattra, MD, FAAP, Allegro</p> <p>11 Pediatrics</p> <p>12 Jeff Gombosky, Pharmaceutical</p> <p>13 Research and Manufacturers of America</p> <p>14 Janel Jorgenson, Washington</p> <p>15 Department of Health</p> <p>16 Libby Page, MPH, King County Public</p> <p>17 Health</p> <p>18 Amy Person, MD, Benton-Franklin</p> <p>19 Health District</p> <p>20 Kristi A. Rice, MD, MultiCare</p> <p>21 Deaconess Hospital</p> <p>22 Michele Roberts, MPH, MCHES,</p> <p>23 Washington Department of Health</p> <p>24 Sherri Zorn, MD, Pediatrician</p>	<p>26</p> <p>27</p> <p>28</p> <p>29</p> <p>30</p> <p>31</p> <p>32</p> <p>33</p> <p>34</p> <p>35</p> <p>36</p> <p>37</p> <p>38</p>	<p><u>WVA</u></p> <p>Julia G. Zell, MA, Esq., Executive</p> <p>Director</p> <p><u>Helms &amp; Company, Inc.</u></p> <p>Patrick Miller, MPH, WVA,</p> <p>Administrative Director</p> <p>Alyssa McKeon, Project Lead</p> <p><u>Other</u></p> <p>Rick Hourigan, MD, MHA, Market</p> <p>Medical Executive, PNW, Cigna</p> <p>Breelyn Young, GSK</p>
---	---	---

**I. Welcome and Introductions**

At 12:02 p.m. Dr. Dunn, substitute Chairman for Dr. Marcuse, called the meeting to order, provided a notice of recording, and took roll call.

**II. Calendar Consent Items**

Dr. Dunn directed the Committee’s attention to the consent item submitted for approval. There being no questions or comments, the following items were put to a vote:

Upon motion duly made and seconded, it was unanimously

**VOTED:** To approve April 8, 2021, meeting minutes.

**III. Committee Charter Review**

Ms. Zell reviewed the Vaccine Committee Charter. The section on committee purpose has been updated with the required statutory reference. The formatting of the key activities section has been updated to create uniformity across committee charters. There have been no changes to the committee meeting frequency and notice or reporting frequency. Committee membership positions have been clarified. Ms. Zell is requesting the Vaccine Committee approve the charter before it is sent to the WVA Board of Directors for final approval.

Ms. Jorgensen requested that the term “Child Profile” be removed from the title of the Director Department Immunization Program position due to program rebranding. The Vaccine Committee discussed the nuances of committee membership and voting vs. non-voting members. Ms. Zell will engage with outside counsel to seek further guidance on committee voting.

64  
65 Upon motion duly made and seconded, it was unanimously  
66

67 **VOTED:** To approve the changes to the Vaccine Committee Charter with the one  
68 suggested change.  
69

#### 70 **IV. Department of Health (DOH)**

71 Ms. Jorgenson presented updates regarding staffing, childhood vaccine uptake, vaccine choice, influenza,  
72 and COVID-19 vaccination. Ms. Jorgenson will continue in her role as Acting Vaccine Section Manager,  
73 Ms. Coiteux will continue as Acting Office Director, and Ms. Roberts will continue as Acting Assistant  
74 Secretary. Ms. Jorgenson shared that her team is in the process of staffing position vacancies while  
75 additional staff are returning from maternity leave. There are plans to increase the size of Ms. Jorgenson's  
76 team.  
77

78 Ms. Jorgenson reviewed a presentation document. She began with a chart showing the monthly vaccines  
79 administered for individuals 0 through 18 years old in Washington State, comparing the average number in  
80 2015-2019 with 2020 and 2021. While there has been an improvement in monthly vaccines administered  
81 from 2020 to 2021, they have not yet reached pre-pandemic levels. Children ages 4 to 6 saw a large  
82 improvement in monthly vaccines administered during August, likely due to the school rule requiring  
83 vaccination for in-person and remote learning. The Committee discussed potential root causes of the lower  
84 rates of vaccination for younger children. Data was unavailable as to changes in size of population or  
85 number of children engaging in remote learning. The Committee also discussed the impact of vaccine  
86 hesitancy on childhood vaccinations.  
87

88 Ms. Jorgenson updated the Committee as to the process of vaccine choice. Ms. Jorgenson offered to share  
89 market data with the Committee once it is compiled. Dr. Zorn inquired as to why there is vaccine choice.  
90 Ms. Zell clarified that vaccine choice is part of the statutory requirements of the WVA.  
91

92 Ms. Jorgenson shared an update on flu vaccination inventory. Currently, 100% of the pre-booked order is  
93 now available. Only 40% of the inventory has been requested by providers. This is lower than previous  
94 years when by November, provider requests amounted to closer to 60% of the allocation.  
95

96 Dr. Dunn asked Dr. Rice and Dr. Chattra to share flu uptake at their practices. Dr. Rice shared that overall  
97 flu uptake is much lower than last year at her practice. Dr. Chattra shared that overall flu uptake has been  
98 strong with three opportunities to offer vaccination: well child checks, other appointments, and drive-thru  
99 clinics. COVID-19 has presented logistical challenges that make flu uptake difficult. Dr. Dunn shared that  
100 he has seen a decline in flu uptake as well. Dr. Zorn said that staffing has presented a logistical challenge  
101 for scheduling flu vaccinations. She also stated that a decrease in the number of family members attending  
102 a doctor's appointment was impacting their ability to distribute flu vaccination.  
103

#### 104 **V. Public Comment**

105 No public comment was given.  
106

#### 107 **VI. Pediatric COVID-19**

108 Ms. Roberts provided an update on pediatric COVID-19 vaccination. Vaccination for 5- to 11-year-olds is  
109 in the process of rolling out. Standing orders from the CDC should be arriving tomorrow. Supplies of the  
110 vaccine will stabilize in the coming weeks. The DOH does not yet know their weekly allocation of pediatric  
111 COVID-19 vaccine. Ms. Roberts reviewed the data on the state dashboard detailing vaccination rates by  
112 age group as well as by county. This data is available to the public. Dr. Dunn noted that vaccination rates  
113 have leveled off. Dr. Rice shared that Providence is still figuring out the logistics of in-office vaccination.

114 Dr. Zorn noted that she cannot track completed vaccination rates through the dashboard. Dr. Chattra said  
115 his practice is seeing high demand with large vaccination clinics filling up. The school districts in the area  
116 are also booking up quickly. Dr. Chattra stated that the old model of hosting vaccine clinics within the  
117 building would not enable his practice to meet demands. Dr. Dunn concurred and said that staffing was the  
118 largest hurdle faced. Ms. Roberts added that after this initial surge in interest, trust will need to be built  
119 through well-child visits.

120

121 **VII. Closing**

122 The meeting adjourned at 1:02 p.m.

**Washington Vaccine Association Assessment Grid**

**FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2022.**

**For Dosage-Based Assessment (DBA) Billing Used for Commercially Insured Patients Under the Age of 19.**

Please note that this WVA Assessment Grid, effective July 1, 2022, replaces the grid last updated on July 1, 2021. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). **The YELLOW COLUMN is the assessment amount per dose as of July 1, 2022.**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2021 to 06/30/2022	For Reference: CDC Private Sector Cost/Dose 04/01/2022	WVA Assessment Amount per dose as from 07/01/2022 to 06/30/2023	Percent Change 07/01/2021 to 07/01/2022
90620	58160-0976-20 (10 pack – 1 dose syringe)	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero®	\$120.84	\$201.30	\$120.84	0.0%
90621	00005-0100-10 (10 pack – 1 dose syringe)	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	Trumenba®	\$115.17	\$168.15	\$115.17	0.0%
90633	58160-0825-52 (10 pack – 1 dose syringe)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	Havrix®	\$20.72	\$35.87	\$20.72	0.0%
	00006-4095-02 (10 pack – 1 dose syringe)		Vaqta®		\$35.61		
90647	00006-4897-00 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	PedvaxHIB®	\$13.54	\$28.05	\$13.54	0.0%
90648	49281-0545-03 (5 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	ActHIB®	\$9.46	\$18.24	\$9.46	0.0%
	58160-0818-11 (10 pack – 1 dose vial)		Hiberix®		\$12.00		
90651	00006-4121-02 (10 pack – 1 dose syringe)	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$189.08	\$253.60	\$189.08	0.0%
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Prevnar 13 TM	\$144.84	\$226.43	\$144.84	0.0%
90680	00006-4047-41 (10 pack – 1 dose tube)	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$72.04	\$90.50	\$72.04	0.0%

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2021 to 06/30/2022	For Reference: CDC Private Sector Cost/Dose 04/01/2022	WVA Assessment Amount per dose as from 07/01/2022 to 06/30/2023	Percent Change 07/01/2021 to 07/01/2022
90681	58160-0854-52 (10 pack – 1 dose vial)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$97.88	\$130.82	\$97.88	0.0%
90696	58160-0812-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$41.93	\$57.22	\$41.93	0.0%
	49281-0562-10 (10 pack – 1 dose vial)		Quadracel™		\$58.36		
	49281-0564-15 (10 pack – 1 dose syringe)						
90697	63361-243-15 (10 pack – 1 dose syringe)	Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate (meningococcal protein conjugate), and Hepatitis B (recombinant) vaccine	Vaxelis™	\$83.38	\$139.82	\$83.38	N/A
	63361-243-10 (10 pack – 1 dose vial)						
90698	49281-0511-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$61.94	\$106.18	\$61.94	0.0%
90700	49281-0286-10 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Daptacel®	\$18.63	\$34.15	\$18.63	0.0%
	58160-0810-52 (10 pack – 1 dose syringe)		Infanrix®		\$37.03		
90702	49281-0225-10 (10 pack – 1 dose vial)	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	DT (pediatric)	\$59.59	\$0.00	\$59.59	0.0%
90707	00006-4681-00 (10 pack – 1 dose vial)	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	M-M-R®II	\$21.77	\$87.31	\$21.77	0.0%
90710	00006-4171-00 (10 pack – 1 dose vial)	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	ProQuad®	\$138.67	\$250.02	\$138.67	0.0%
90713	49281-0860-10 (10 dose vial)	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	IPOL®	\$13.90	\$38.74	\$13.90	0.0%

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2021 to 06/30/2022	For Reference: CDC Private Sector Cost/Dose 04/01/2022	WVA Assessment Amount per dose as from 07/01/2022 to 06/30/2023	Percent Change 07/01/2021 to 07/01/2022
90714	49281-0215-15 (10 pack – 1 dose syringe)	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	Tenivac®	\$16.42	\$37.92	\$16.42	0.0%
	49281-0215-10 (10 pack – 1 dose vial)						
	13533-0131-01 (10 pack – 1 dose vial)	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use	TDVAX™		\$37.17		
90715	58160-0842-11 (10 pack – 1 dose vial)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	Boostrix®	\$32.73	\$44.80	\$32.73	0.0%
	58160-0842-52 (10 pack – 1 dose syringe)						
	49281-0400-10 (10 pack – 1 dose vial)		Adacel®		\$50.48		
	49281-0400-20 (5 pack – 1 dose syringe)						
90716	00006-4827-00 (10 pack – 1 dose vial)	Varicella virus vaccine (VAR), live, for subcutaneous use	Varivax®	\$110.28	\$150.98	\$110.28	0.0%
90723	58160-0811-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	Pediarix®	\$60.96	\$90.05	\$60.96	0.0%
90732	00006-4837-03 (10 pack – 1 dose syringe)	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years	Pneumovax®23	\$59.78	\$117.08	\$59.78	0.0%
90734	49281-0589-05 (5 pack – 1 dose vial)	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	Menactra®	\$96.15	\$141.70	\$96.15	0.0%
	58160-0955-09 (5 pack – 1 dose vial)		Menveo®		\$144.18		
90619	49281-0590-05 (5 pack – 1 dose vial)	Meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine .5mL dose, preservative free	MedQuadfi™	\$96.15	\$148.71	\$96.15	N/A

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2021 to 06/30/2022	For Reference: CDC Private Sector Cost/Dose 04/01/2022	WVA Assessment Amount per dose as from 07/01/2022 to 06/30/2023	Percent Change 07/01/2021 to 07/01/2022
90744	00006-4981-00 (10 pack – 1 dose vial)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$12.54	\$35.60	\$12.54	-27.8%
	00006-4093-02 (10 pack – 1 dose syringe)		Recombivax HB®		\$35.60		
	58160-0820-52 (10 pack – 1 dose syringe)		Engerix B®		\$26.34		
<b>2021-2022 Pediatric Influenza Vaccine Assessments</b>							
90686	19515-0808-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent	\$13.50	\$19.00	\$13.50	0.0%
	49281-0422-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR		\$18.63		
90688	49281-0637-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV	\$13.55	\$18.63	\$13.55	0.0%
90672	66019-0309-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent	\$18.88	\$22.95	\$18.88	0.0%
90674	70461-0322-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent	\$16.02	\$26.95	\$16.02	0.0%

**NOTE: The WVA reserves the right to modify the Assessment Grid in effect at any time with Board approval and appropriate notification of payers.**

<b>DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2022</b>							
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename				
90686	19515-0818-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent				
	49281-0421-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR				

90688	49281-0635-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0321-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent

**DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2021**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0816-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0420-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0635-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0321-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent

**DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2020**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0906-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0419-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90672	66019-0306-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90688	49281-0631-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV

90674	70461-0319-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent				
<b>DISCONTINUED CPT CODES FROM JULY 1, 2020 ASSESSMENT GRID</b>							
CPT Code	NDC Code / Packaging	July 1, 2021 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2020	CDC Private Sector Cost/Dose 4/1/2021	WVA Assessment Amount per dose as of 7/1/2021	Percent change 7/1/2021 to 7/1/2022
90680	00006-4047-20 (25 pack - 1 dose tube)	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$72.04	\$87.88	\$72.04	0.0%
90696	58160-0812-11 (10 pack - 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$41.93	\$55.64	\$41.93	0.0%
90698	49281-0510-05 (5 pack - 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$61.94	\$61.94	\$61.94	0.0%
90700	58160-0810-11 (10 pack - 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Infanrix®	\$18.63	\$26.31	\$18.63	0.0%
<b>DISCONTINUED CPT CODES FROM JULY 1, 2019 ASSESSMENT GRID</b>							
CPT Code	NDC Code / Packaging	July 1, 2019 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change 7/1/2018 to 7/1/2019
90636	58160-0815-52 (10 pack - 1 dose syringe)	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use.  (Age 18 only for CVP)	Twinrix®	\$76.58	\$104.00	\$67.29	-12.1%
<b>DISCONTINUED CPT CODES FROM JULY 1, 2018 ASSESSMENT GRID</b>							
CPT Code	NDC Code / Packaging	July 1, 2018 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change 7/1/2018 to 7/1/2019

90685	49281-0518-25 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	<b>Fluzone Pediatric Preservative Free (PF)</b>	\$23.16	\$19.26	\$18.53	-20.0%
<b>DISCONTINUED CPT CODES FROM JULY 1, 2017 ASSESSMENT GRID</b>							
CPT Code	NDC Code	July 1, 2017 Grid CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2016	CDC Market Survey	WVA Assessment Amount per dose as of 7/1/2017	Percent change 7/1/2016 to 7/1/2017
90644	58160-0801-11	Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hb-MenCY), 4 dose schedule, when administered to high risk children 2 - 15 months of age, for intramuscular use	<b>MenHibrix</b>	\$14.72	\$24.71	\$14.72	0.0%
90649	00006-4045-41	Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	<b>Gardasil</b>	n/a	n/a	n/a	n/a
90650	58160-0830-52	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	<b>Cervarix</b>	n/a	n/a	n/a	n/a
90743	00006-4981-00	Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	<b>Recombivax HB</b>	\$17.19	\$23.20	\$17.19	0.0%
90685	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	<b>Fluzone Pediatric Preservative Free (PF)</b>	\$23.16	\$18.72	\$23.16	0.0%
90687	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use	<b>Fluzone</b>	\$18.47	\$18.72	\$18.47	0.0%

To ensure proper DBA submission and carrier/TPA remittance to the WVA, providers should check the:

- **Date of service** to ensure the correct Grid year is being used;
- **CPT code** to ensure it is a valid code (\*see **note** below); and
- **Assessment amount** to ensure proper DBA submission and carrier/TPA remittance to the WVA.

\*Please note: Sometimes vaccine material is still viable and can be administered, even if it has been discontinued from prior Grids and is not shown on the current Grid. If the CPT code is not offered on the current Grid, providers should check the legacy information at the end of the grid document to determine if a prior Grid amount should be billed on the DBA.

# WANT TO JOIN PIERCE COUNTY IMMUNIZATION COALITION?

## Who are we?

- A non-profit organization of community partners with a mission to promote immunizations across the lifespan

## How do we do this?

- Provider and community education
- Legislative advocacy

## Who can join?

- Anyone who wants to help us achieve our mission!
- Healthcare providers and community members welcome

## When do we meet?

- Generally, the last Friday of every month
- Next meeting is May 20 from 7-8:30am (Zoom)

## Where?

- Virtual for now – please contact [piercecountyimmscoalition@gmail.com](mailto:piercecountyimmscoalition@gmail.com) to join



Follow us on Facebook!

<https://www.facebook.com/PierceCountyImmunizationCoalition/>



## ***What's Up Doc? Spring Webinars***

All three webinars will be held during lunchtime, from 12:15pm to 1pm on Zoom.

- April 22 - Vaccines of the Future - Dr. Deborah Fuller, UW Microbiology
- May 6 - How to Maintain Immunization Rates in a Short-Staffed Environment - Lummi Tribal Health Center, Virginia Mason University Village Pediatrics, Allegro Pediatrics
- May 13 - Navigating Polarizing Vaccine Conversations - Dr. Gretchen LaSalle

Contact [piercecountyimmscoalition@gmail.com](mailto:piercecountyimmscoalition@gmail.com) for an invite